Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | -41.73% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.36 | N/A | -41.73% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions impacting performance. They highlighted their commitment to strategic initiatives.
Management acknowledged challenges in meeting earnings expectations.
They emphasized ongoing efforts to improve operational efficiency.
This earnings report indicates that Biocryst Pharmaceuticals is struggling to meet expectations, particularly in terms of earnings per share. The stock fell 17.07% following the announcement, reflecting investor disappointment. Without clear guidance or revenue figures, uncertainty remains about the company's future performance and strategy.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Aug 1, 2011